Mosley Juan F, Smith Lillian L, Brantley Patricia, Locke Dustin, Como Madison
P T. 2017 Oct;42(10):638-640.
Vaxchora is the first vaccine approved by the Food and Drug Administration for the prophylaxis of cholera infection. Cholera, a potentially life-threatening bacterial infection that occurs in the intestines and causes severe diarrhea and dehydration, has a low incidence in the U.S., but a high incidence in Africa, Southeast Asia, and other locations around the world. These areas draw travelers from the U.S., so cholera can present in patients who return from visits to these regions. Previous means of prophylaxis included the use of doxycycline for the prevention of traveler's diarrhea, but doxycycline is not specific for cholera. With the approval of Vaxchora, a live attenuated, single-dose, oral suspension vaccine, travelers can now visit these areas with less chance of contracting the bacterium which causes cholera infections.
Vaxchora是美国食品药品监督管理局批准的第一种用于预防霍乱感染的疫苗。霍乱是一种发生在肠道内的、可能危及生命的细菌感染，可导致严重腹泻和脱水。在美国，霍乱发病率较低，但在非洲、东南亚和世界其他地区发病率较高。这些地区吸引来自美国的旅行者，因此从这些地区旅行归来的患者可能会感染霍乱。以前的预防方法包括使用强力霉素预防旅行者腹泻，但强力霉素对霍乱并无特异性。随着减毒活单剂量口服混悬液疫苗Vaxchora的获批，旅行者前往这些地区时感染导致霍乱的细菌的几率降低了。
